USANA Health Sciences, Inc. (NYSE:USNA) Director Myron W. Wentz sold 100,000 shares of USANA Health Sciences stock in a transaction that occurred on Friday, May 25th. The shares were sold at an average price of $115.00, for a total transaction of $11,500,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
USANA Health Sciences opened at $112.60 on Friday, according to Marketbeat.com. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of 27.73 and a beta of 0.76. USANA Health Sciences, Inc. has a 12-month low of $52.80 and a 12-month high of $121.15.
USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, April 24th. The company reported $1.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.14. USANA Health Sciences had a net margin of 6.47% and a return on equity of 27.92%. The business had revenue of $292.00 million during the quarter, compared to analysts’ expectations of $268.93 million. During the same period in the previous year, the company earned $0.91 earnings per share. USANA Health Sciences’s revenue for the quarter was up 14.4% on a year-over-year basis. equities research analysts predict that USANA Health Sciences, Inc. will post 4.4 EPS for the current fiscal year.
A number of analysts have issued reports on USNA shares. Pivotal Research lifted their target price on shares of USANA Health Sciences from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. TheStreet cut shares of USANA Health Sciences from a “b+” rating to a “c+” rating in a research note on Tuesday, February 6th. Finally, ValuEngine upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $95.00.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.